Whether the safe use of thrombin inhibitors may confer TF-associated anti-fibrotic activity in patients with hepatitis C-related liver fibrosis requires validation with measures of TF activity in larger interventional studies. This evidence concerns the gene TF and hepatitis C virus infection.